Skip to main content

Formulary Coverage

Best access among specialty systemic therapies indicated
for AD1,a,b

Most efficient path to starting treatment for most patientsc

  • ≈99% of commercial AD patients (6+ months of age) nationally are covered for DUPIXENT
  • ≈90% of commercial patient lives have to fail only 1 or 2 prescription topical treatments

aMMIT Analysis June 2025. Analysis included DUPIXENT, tralokinumab, upadacitinib, abrocitinib, lebrikizumab, and nemolizumab.

bBased on available published commercial UM coverage criteria.

cLeast step edits to biologics and oral JAKis in AD.

icon search

Check the formulary status for DUPIXENT in your area

See coverage status, prior authorization, and step therapy information

US.DUP.25.04.0473

Questions?

For questions or a full benefits
investigation for your patient, contact

DUPIXENT MyWay® at 1‑844‑
DUPIXEN(T) (1‑844‑387‑4936),
Monday‑Friday, 8am‑9pm ET

DUPIXENT MyWay®

EXPLORE patient Support RESOURCES